Post by Colby Kash

A Zoom call with a startup founder in Israel. Missile alarm goes off. Drops everything, runs to the bomb shelter. Fifteen minutes later, back on screen, picking up mid-sentence explaining a scientific mechanism for curing cancer. Rinse. Repeat. This is what it has been like with our counterparts in Israel the last three years: founders, investors, teammates. Technologists and doctors by day, intelligence reserve duty by night. How do you compete with that kind of resolve? How do you compete with the highest concentration of R&D spend and unicorns per capita on Earth? You don’t. At Camelot, we look to partner. 🇮🇱 🇮🇱 🇮🇱 This week’s SciNance Report covers the life science investment opportunity in Israel, benchmarked against cyber, defense, and AI, drawn from meetings with hospital systems, tech transfer offices, investors, and founders on the ground. Ohad Shahar Peter Kash Tomer Aharonovitch Eran Zakut Nadav Berger Rachel Diamant Zacki Turkeltaub Shlomo Noy Anat Naschitz Sariel Moshe Yaron Kniajer Jared Kash Yaron Daniely Yael Gruenbaum-Cohen Dr. Keren-Or Amar Orit Nativ Matan Sturlesi Shirley Shahar Liat Bidas Sharon Kaplinsky Mati Gill Noam Diamant David Baram Ronen Gadot Haim Zilbershats Yoav S. https://lnkd.in/e6QEJQtT